Real-World safety study launches for colorectal cancer drug fruquintinib
NCT ID NCT07035886
First seen Dec 29, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tracks side effects and safety of the drug fruquintinib (Fruzaqla) in 600 adults with colorectal cancer in South Korea. Participants take the drug as prescribed by their doctor. The goal is to see how often side effects occur in everyday use, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Hospital
RECRUITINGSeoul, 03722, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.